Quest Diagnostics price target raised to $74 from $68 at Maxim Maxim raised its price target for Quest Diagnostics shares to $74 following the company's Q2 and recommends investors buy the stock. The firm reiterates a Buy rating on the name.
LabCorp downgraded to Hold from Buy at Deutsche Bank Deutsche Bank downgraded LabCorp (LH) to Hold saying revenue synergies from the Covance (CVD) acquisition are "hard to envision." The firm believes LabCorp is now less of a pure play in the Clinical Labs space and lowered its price target for shares to $115 from $120. Deutsche coupled the downgrade with an upgrade of peer Quest (DGX).